Sulfoglycodendrimer Therapeutics for HIV‐1 and SARS‐CoV‐2

Hexavalent sulfoglycodendrimers (SGDs) are synthesized as mimics of host cell heparan sulfate proteoglycans (HSPGs) to inhibit the early stages in viral binding/entry of HIV‐1 and SARS‐CoV‐2. Using an HIV neutralization assay, the most promising of the seven candidates are found to have sub‐micromol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Adv Ther (Weinh)
Main Authors: Wells, Lauren, Vierra, Cory, Hardman, Janee’, Han, Yanxiao, Dimas, Dustin, Gwarada‐Phillips, Lucia N., Blackeye, Rachel, Eggers, Daryl K., LaBranche, Celia C., Král, Petr, McReynolds, Katherine D.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Full Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7995185/
https://ncbi.nlm.nih.gov/pubmed/33786368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adtp.202000210
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados